🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT05071131
Recruiting Not applicable

Effect of Inulin on Gut Microbiota and Gut Barrier in Chronic Kidney Disease

NCT05071131 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2022-02-01
Last updated
2024-06-25

Condition(s) studied

Chronic Kidney Disease 5D

Investigational drug(s) / intervention(s)

InulinPlacebo

Inulin: 1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days

Placebo: 1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days

Study summary

An adequate fiber intake is crucial for a well-balanced diet and reduces the risk of chronic diseases. However, nutritional recommendations for chronic kidney disease patients lead to an insufficient fiber intake with possible maladaptive effects on the gut microbiome. Therefore, we want to study the effects of a 35-day inulin supplementation on the gut microbiome, gut barrier function, bacterial metabolites and immune cell states in chronic kidney disease patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Men and women in a ratio of 1:1 * Age 18-75 years * Body mass index 25.0 - 39.9 kg/m\^2 * End-stage kidney disease, which has been treated regularly with hemodialysis for at least 3 months Exclusion Criteria: * Malignant diseases * Recent or current hospitalization * Postoperative phase * Acute infections * Malnutrition * Antibiotic treatment within the last 4 weeks * Regular intake of probiotics and/or prebiotics * Change of body weight of more than 2 kg in the month prior to study entry * Known drug or alcohol abuse Changes applied in July 2022 according to amendment no. 1: * Two inclusion criteria were changed to improve recruitment * Age range was changed from 18-70 to 18-75 years * BMI range was changed from 18.5 - 34.9 to 25.0 - 39.9 kg/m\^2 * The intervention scheme was adapted to increase patient adherence * A 7-day adaption phase with half of the dose (15 grams per day) at the start of the intervention was introduced, changing treatment duration from 28 to 35 days Changes applied in January 2024 according to amendment no. 2: * One inclusion criteria was changed to improve recruitment * BMI range was changed from 25 - 39,9 to 18,5 - 39,9 kg/m² * Last visit was brought foward by 4 weeks.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Experimental and Clinical Research Center Berlin Germany Recruiting

More Charite University, Berlin, Germany trials in Germany

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05071131 on ClinicalTrials.gov ↗ ← All trials in Germany